Fine tuning of receptor-selectivity for tumor necrosis factor-α using a phage display system with one-step competitive panning

Biomaterials

Volumn 32, Issue 23, 2011, Pages 5498-5504

  Abe, Yasuhiro ^a   Yoshikawa, Tomoaki ^a,b   Inoue, Masaki ^a   Nomura, Tetsuya ^a   Furuya, Takeshi ^a,b   Yamashita, Takuya ^a,b   Nagano, Kazuya ^a   Nabeshi, Hiromi ^a,b   Yoshioka, Yasuo ^a,b   Mukai, Yohei ^a,b   Nakagawa, Shinsaku ^b   Kamada, Haruhiko ^a,b   Tsutsumi, Yasuo ^a,b   Tsunoda, Shin ichi ^a,b  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Affinity; Bioactivity; Cytokine; Molecular biology; Protein

Indexed keywords

AFFINITY; ANTI-INFLAMMATORIES; ANTITUMOR DRUGS; CYTOKINE; FINE TUNING; INFLAMMATORY DISEASE; MUTANT PROTEINS; PHAGE DISPLAY; SCREENING TECHNIQUES; STRUCTURE-FUNCTION RELATIONSHIP; TUMOR NECROSIS FACTORS; TUMOR PROGRESSIONS; WILD TYPES;

BIOACTIVITY; CLONING; GLYCOPROTEINS; MACROPHAGES; MOLECULAR BIOLOGY; TUMORS;

DISPLAY DEVICES;

CYCLOHEXIMIDE; MUTANT PROTEIN; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOSENSOR; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; HUMAN; HUMAN CELL; PHAGE DISPLAY; PRIORITY JOURNAL; RECEPTOR BINDING; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY;

ADIPOCYTES; AMINO ACID SUBSTITUTION; ANIMALS; BINDING SITES; BINDING, COMPETITIVE; BIOSENSING TECHNIQUES; CELL LINE; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; KINETICS; MICE; PEPTIDE LIBRARY; PROTEIN BINDING; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79956332121     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.04.018     Document Type: Article

References (44)

1. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003, 3(9):745-756.
2. Szlosarek P.W., Balkwill F.R. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 2003, 4(9):565-573.
3. Aderka D., Engelmann H., Maor Y., Brakebusch C., Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992, 175(2):323-329.
4. Feldmann M., Maini R.N. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 2003, 9(10):1245-1250.
5. Muto Y., Nouri-Aria K.T., Meager A., Alexander G.J., Eddleston A.L., Williams R. Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure. Lancet 1988, 2(8602):72-74.
6. Thorbecke G.J., Shah R., Leu C.H., Kuruvilla A.P., Hardison A.M., Palladino M.A. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A 1992, 89(16):7375-7379.
7. Williams R.O., Feldmann M., Maini R.N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 1992, 89(20):9784-9788.
8. Gomez-Reino J.J., Carmona L., Valverde V.R., Mola E.M., Montero M.D. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003, 48(8):2122-2127.
9. Lubel J.S., Testro A.G., Angus P.W. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 2007, 37(10):705-712.
10. Leist M., Gantner F., Jilg S., Wendel A. Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release. J Immunol 1995, 154(3):1307-1316.
11. Mori L., Iselin S., De Libero G., Lesslauer W. Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J Immunol 1996, 157(7):3178-3182.
12. Ware C.F., Crowe P.D., Vanarsdale T.L., Andrews J.L., Grayson M.H., Jerzy R., et al. Tumor necrosis factor (TNF) receptor expression in T lymphocytes. Differential regulation of the type I TNF receptor during activation of resting and effector T cells. J Immunol 1991, 147(12):4229-4238.
13. Irwin M.W., Mak S., Mann D.L., Qu R., Penninger J.M., Yan A., et al. Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium. Circulation 1999, 99(11):1492-1498.
14. Dopp J.M., Sarafian T.A., Spinella F.M., Kahn M.A., Shau H., de Vellis J. Expression of the p75 TNF receptor is linked to TNF-induced NFkappaB translocation and oxyradical neutralization in glial cells. Neurochem Res 2002, 27(11):1535-1542.
15. Yang L., Lindholm K., Konishi Y., Li R., Shen Y. Target depletion of distinct tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival through different signal transduction pathways. J Neurosci 2002, 22(8):3025-3032.
16. Ban L., Zhang J., Wang L., Kuhtreiber W., Burger D., Faustman D.L. Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism. Proc Natl Acad Sci U S A 2008, 105(36):13644-13649.
17. Monden Y., Kubota T., Inoue T., Tsutsumi T., Kawano S., Ide T., et al. Tumor necrosis factor-alpha is toxic via receptor 1 and protective via receptor 2 in a murine model of myocardial infarction. Am J Physiol Heart Circ Physiol 2007, 293(1):H743-H753.
18. Wang M., Crisostomo P.R., Markel T.A., Wang Y., Meldrum D.R. Mechanisms of sex differences in TNFR2-mediated cardioprotection. Circulation 2008, 118(Suppl. 14):S38-S45.
19. Arnett H.A., Mason J., Marino M., Suzuki K., Matsushima G.K., Ting J.P. TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 2001, 4(11):1116-1122.
20. Faustman D., Davis M. TNF receptor 2 p.thway: drug target for autoimmune diseases. Nat Rev Drug Discov 2010, 9(6):482-493.
21. Fontaine V., Mohand-Said S., Hanoteau N., Fuchs C., Pfizenmaier K., Eisel U. Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. J Neurosci 2002, 22(7). RC216.
22. MacEwan D.J. TNF receptor subtype signalling: differences and cellular consequences. Cell Signal 2002, 14(6):477-492.
23. Mukai Y., Shibata H., Nakamura T., Yoshioka Y., Abe Y., Nomura T., et al. Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant. J Mol Biol 2009, 385(4):1221-1229.
24. Shibata H., Yoshioka Y., Ohkawa A., Minowa K., Mukai Y., Abe Y., et al. Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist. J Biol Chem 2008, 283(2):998-1007.
25. Yamamoto Y., Tsutsumi Y., Yoshioka Y., Nishibata T., Kobayashi K., Okamoto T., et al. Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity. Nat Biotechnol 2003, 21(5):546-552.
26. Abe Y., Yoshikawa T., Kamada H., Shibata H., Nomura T., Minowa K., et al. Simple and highly sensitive assay system for TNFR2-mediated soluble- and transmembrane-TNF activity. J Immunol Methods 2008, 335(1-2):71-78.
27. Schwarz M., Rottgen P., Takada Y., Le Gall F., Knackmuss S., Bassler N., et al. Single-chain antibodies for the conformation-specific blockade of activated platelet integrin alphaIIbbeta3 designed by subtractive selection from naive human phage libraries. Faseb J 2004, 18(14):1704-1706.
28. Popkov M., Rader C., Barbas C.F. Isolation of human prostate cancer cell reactive antibodies using phage display technology. J Immunol Methods 2004, 291(1-2):137-151.
29. Eisenhardt S.U., Schwarz M., Bassler N., Peter K. Subtractive single-chain antibody (scFv) phage-display: tailoring phage-display for high specificity against function-specific conformations of cell membrane molecules. Nat Protoc 2007, 2(12):3063-3073.
30. Shibata H., Yoshioka Y., Abe Y., Ohkawa A., Nomura T., Minowa K., et al. The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF. Biomaterials 2009, 30(34):6638-6647.
31. Shibata H., Yoshioka Y., Ikemizu S., Kobayashi K., Yamamoto Y., Mukai Y., et al. Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window. Clin Cancer Res 2004, 10(24):8293-8300.
32. Wajant H., Pfizenmaier K., Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003, 10(1):45-65.
33. Weiss T., Grell M., Siemienski K., Muhlenbeck F., Durkop H., Pfizenmaier K., et al. TNFR80-dependent enhancement of TNFR60-induced cell death is mediated by TNFR-associated factor 2 and is specific for TNFR60. J Immunol 1998, 161(6):3136-3142.
34. Fotin-Mleczek M., Henkler F., Samel D., Reichwein M., Hausser A., Parmryd I., et al. Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8. J Cell Sci 2002, 115(Pt. 13):2757-2770.
35. Yamagishi J., Kawashima H., Matsuo N., Ohue M., Yamayoshi M., Fukui T., et al. Mutational analysis of structure-activity relationships in human tumor necrosis factor-alpha. Protein Eng 1990, 3(8):713-719.
36. Barbara J.A., Smith W.B., Gamble J.R., Van Ostade X., Vandenabeele P., Tavernier J., et al. Dissociation of TNF-alpha cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNF-alpha mutants. Embo J 1994, 13(4):843-850.
37. Van Ostade X., Vandenabeele P., Everaerdt B., Loetscher H., Gentz R., Brockhaus M., et al. Human TNF mutants with selective activity on the p55 receptor. Nature 1993, 361(6409):266-269.
38. Loetscher H., Stueber D., Banner D., Mackay F., Lesslauer W. Human tumor necrosis factor alpha (TNF alpha) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors. J Biol Chem 1993, 268(35):26350-26357.
39. Abe Y., Nomura T., Yoshioka Y., Kamada H., Tsunoda S., Tsutsumi Y. Anti-inflammatory effects of a Novel TNFR1-selective antagonistic TNF mutant on established murine collagen-induced arthritis. Adv Exp Med Biol 2011, 691:493-500.
40. Yoshioka Y., Watanabe H., Morishige T., Yao X., Ikemizu S., Nagao C., et al. Creation of lysine-deficient mutant lymphotoxin-alpha with receptor selectivity by using a phage display system. Biomaterials 2010, 31(7):1935-1943.
41. Eck M.J., Sprang S.R. The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. J Biol Chem 1989, 264(29):17595-17605.
42. Van Ostade X., Tavernier J., Fiers W. Structure-activity studies of human tumour necrosis factors. Protein Eng 1994, 7(1):5-22.
43. Idriss H.T., Naismith J.H. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech 2000, 50(3):184-195.
44. Mukai Y., Nakamura T., Yoshikawa M., Yoshioka Y., Tsunoda S., Nakagawa S., et al. Solution of the structure of the TNF-TNFR2 complex. Sci Signal 2010, 3(148). ra83.